Poseida Therapeutics Inc reports results for the quarter - Earnings Summary
09/11/2024 12:27
* Poseida Therapeutics Inc PSTX.OQ reported quarterly
adjusted
earnings of 21 cents per share for the quarter , higher than
the same quarter last year, when the company reported EPS of -35
cents. The mean expectation of five analysts for the quarter
was for a loss of 41 cents per share. Wall Street expected
results to range from -48 cents to -33 cents per share.
* Revenue rose 667.2% to $71.75 million from a year ago;
analysts
expected $16.27 million.
* Poseida Therapeutics Inc's reported EPS for the quarter
was 21
cents.
* The company reported quarterly net income of $20.24
million.
* Poseida Therapeutics Inc shares had risen by 2.4% this
quarter and lost 12.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Poseida
Therapeutics Inc is 12.00
This summary was machine generated from LSEG data November 9 at
12:27 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.41 0.21 Beat
Jun. 30 2024 -0.41 -0.32 Beat
Mar. 31 2024 -0.42 -0.25 Beat
Dec. 31 2023 -0.39 -0.27 Beat